AbbVie takes option on Argenx’s cancer immunotherapy
ARGX-115 is still in preclinical development
X
AbbVie takes option on Argenx’s cancer immunotherapy
https://pharmaphorum.com/news/abbvie-takes-option-on-argenxs-cancer-immunotherapy/
ARGX-115 is still in preclinical development